The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China

The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China

Abstract Background According to several studies, ROS1 rearrangement is associated with thrombotic risk in non-small cell lung cancer (NSCLC). However, there is no clear understanding of the predictors and prognostic impact of thromboembolic events (TEEs) in patients with advanced ROS1 rearrangement...

Full description

Bibliographic Details
Main Authors:	Jiawen Yi, Huang Chen, Jie Li, Xingran Jiang, Yan Xu, Mengzhao Wang, Zheng Wang, Zhenguo Zhai, Yanhong Ren, Yuhui Zhang
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	Thrombosis Journal
Subjects:	Non-small cell lung cancer Advanced Thromboembolic events ROS1 rearrangement
Online Access:	https://doi.org/10.1186/s12959-022-00417-8

Similar Items

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
by: Chi‐Hao Wu, et al.
Published: (2021-11-01)

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
by: K. K. LAKTIONOV, et al.
Published: (2017-06-01)

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report
by: Shikang Zhao, et al.
Published: (2021-10-01)

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis
by: Yutaka Takahara, et al.
Published: (2020-01-01)

Progress of non-small-cell lung cancer with ROS1 rearrangement
by: Xin Yang, et al.
Published: (2023-12-01)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
by: Rossi G, et al.
Published: (2017-07-01)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
by: Yongchang Zhang, et al.
Published: (2021-09-01)

ROS1-Rearranged Lung Adenocarcinoma: From Molecular Genetics to Target Therapy
by: Ugo Testa, et al.
Published: (2023-08-01)

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
by: Liang Dong, et al.
Published: (2018-01-01)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
by: Shuguang Xu, et al.
Published: (2019-08-01)

Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
by: Angela Napolitano, et al.
Published: (2023-10-01)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022-01-01)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
by: Matthew S. Lara, BS, et al.
Published: (2022-12-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
by: Shibo Wu, et al.
Published: (2018-07-01)

Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study
by: Lei Wang, et al.
Published: (2023-05-01)

Rheumatoid arthritis and venous thromboembolic events
by: M. A. Satybaldyeva
Published: (2016-10-01)

FACTORS ASSOCIATED WITH D-DIMER ELEVATION IN PATIENTS WITH VENOUS THROMBOEMBOLIC EVENTS
by: N. M. Vorobyeva, et al.
Published: (2012-08-01)

Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
by: Jessica Tsukamoto, et al.
Published: (2018-10-01)

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study
by: Fitalew Tadele Admasu, et al.
Published: (2023-05-01)

Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients
by: Yu-Sheng Lin, et al.
Published: (2021-12-01)

Risk factors for venous thromboembolic events and their association with D-dimer level
by: N M Vorobyeva, et al.
Published: (2010-08-01)

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase (RTK) inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-a-, NTRK1-) non-small cell lung cancer globally?
by: Sai-Hong Ignatius Ou
Published: (2014-04-01)

Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study
by: Francesca Futura Bernardi, et al.
Published: (2023-10-01)

Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients
by: Kristina Boss, et al.
Published: (2021-02-01)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
by: Amanda J. W. Gibson, et al.
Published: (2022-03-01)

Evaluating Post-discharge Thromboembolic Events in Patients With COVID-19
by: Maryam Taherkhani, et al.
Published: (2022-05-01)

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Xiaohan Qian, et al.
Published: (2021-04-01)

Prevention of venous thromboembolic events in ischemic stroke
by: Vladimir Anatolyevich Parfenov
Published: (2013-11-01)

Venous thromboembolism in non-small cell lung cancer patients: retrospective analysis of cases treated at the Oncology Day Hospital of Novara, Italy
by: Roberta Buosi, et al.
Published: (2013-04-01)

Risk factors for venous thromboembolic events in patients with rheumatoid arthritis
by: M. A. Satybaldyeva, et al.
Published: (2016-10-01)

Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19
by: Cristina Tudoran, et al.
Published: (2022-08-01)

Deepening the Knowledge of <i>ROS1</i> Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
by: Giorgia Guaitoli, et al.
Published: (2021-11-01)

Using machine learning and big data for the prediction of venous thromboembolic events after spine surgery: A single-center retrospective analysis of multiple models on a cohort of 6869 patients
by: Benjamin S Hopkins, et al.
Published: (2023-01-01)

Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study
by: Hirotsugu Kenmotsu, et al.
Published: (2021-02-01)

Thromboembolic events in ß-Thalassemia major patients
by: Sawsan S. Abbas
Published: (2007-01-01)

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
by: Brigida Stanzione, et al.
Published: (2023-07-01)

Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India
by: Aravind P. Gandhi, et al.
Published: (2023-03-01)

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
by: Chang Lu, et al.
Published: (2020-04-01)

VALUE OF THROMBOEMBOLIC PROPHYLAXIS IN PREVENTION OF THE THROMBOEMBOLISM IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
by: Gorana Rancic, et al.
Published: (2006-07-01)